IgAN

Novartis touts surrogate endpoint win, nabs priority review for Fabhalta in IgAN
Fierce Pharma
Mon, 04/15/24 - 09:32 pm
Novartis
Fabhalta
IgAN
priority review
FDA
ERA 2023 – longer is stronger for Vera
EP Vantage
Tue, 06/20/23 - 09:59 am
ERA
Vera Therapeutics
IgAN
atacicept
immunoglobulin A nephropathy
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Businesswire
Mon, 08/29/22 - 10:26 am
Alnylam Pharmaceuticals
clinical trials
cemdisiran
Regeneron
IgAN
immunoglobultin A nephropathy
RNAi